Fundraising FoxRA Capital — 2017 Investments
4 investments dated 2017 · listed companies and verified rows first · show all
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.
BiotechCambridge, US
Ankit Mahadevia(Executive Officer, Director)inStephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in
BoardJean-Francois Formela(Director)inCasper Breum(Director)
Board seatReza Halse· per SEC Form D
Co-investorsGV (Google Ventures)HEALTHCARE ROYALTY PARTNERSMRL Ventures FundOUP (Osage University Partners)AlphabetAtlas Venture+1 more
Ivantis was a medical device company founded in 2007 in Irvine, California, that developed the Hydrus Microstent, a minimally invasive device for treating glaucoma during cataract surgery.
Irvine, US
David Van Meter(Executive Officer, Director)
BoardTara Butler(Director)Douglas Roeder(Director)Ali Behbahani(Director)inRandy Alexander(Director)Thong Yuen Poon(Director)
Co-investorsAscension VenturesForesite CapitalMemorialCare Innovation FundNew Enterprise Associates (NEA)
PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function.
BiotechHealthtechCranbury, US
David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Director)
BoardPeter Thompson(Director)inSteve Winick(Director)Arnold Oronsky(Director)
Co-investorsAvoro Capital AdvisorsNextech InvestOUP (Osage University Partners)Viking GlobalWellington ManagementOrbiMed+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.